YABANCI DİLDE YAYIN LİSTESİ

Paylaşın
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  

Published Papers In Peer Reviewed Journals

  1. Meriç M, Adalet K, Koylan N, Karabulut N, Arseven A, Ertem G: Treatment of essential hypertension. A comparative study of labetalol and propranolol. Clin. Trials J., 25: 181- 194, 1988.
  2. Meriç M, Gören T, Atılgan D, Eren N, Çubukçu A, Koylan N: Metabolic, hematological, and cardiac effects of long- term Isradipine treatment in mild- to- moderate essential hypertension. J Cardiovasc Pharmacol 1992;19 Suppl 3:S58-60.
  3. Yılmaz E, Adalet K, Yılmaz G, Badur S, Erzengin F, Koylan N, Özsaruhan Ö, Ertem G, Büyüköztürk K: Importance of serum anticardiolipin antibody levels in coronary heart disease. Clin Cardiol 17:117- 121, 1994.
  4. Koylan N, Öncül A, Mercanoğlu F, Orak E, Erzengin F, Büyüköztürk K: The acute effects of cilazapril on left ventricular diastolic functions. J Cardiovasc Pharmacol 24 (Suppl. 3): S42- S44, 1994.
  5. Özsaruhan Ö, Öncül A, Nişancı Y, Umman S, Koylan N, Emel O, Büyüköztürk K, Ertem G: Influence of global system of mobile telephones on permanent pacemakers. Reblampa 8: 157- 158, 1995.
  6. Umman B, Meriç M, Umman S, Koylan N, Adalet K, Nişancı Y, Ertem G: The effects of coronary angioplasty on the global and regional left ventricular function in patients with angina pectoris after anterior myocardial infarction. Int J Angiol 6:199-202, 1997.
  7. Buğra Z, Koylan N, Vural A, Erzengin F, Umman B, Yilmaz E, Meric M, Buyukozturk K. Left ventricular geometric patterns and QT dispersion in untreated essential hypertension. Am J Hypertens 11(10):1164-70, 1998.
  8. Onat A, Soydan I, Tokgözoğlu L, Sansoy V, Koylan N, Domaniç N, Ural D for the Riskburden Study Group: Guideline implementation in a multicenter study with an estimated 44% relative cardiovascular event risk reduction. CLINICAL CARDIOLOGY 26(5): 243- 249, 2003.
  9. Oflaz H, Turkmen A, Kocaman O, Erdogan D, Meric M, Oncul A, Koylan N, Yılmaz E, Yilmaz C, Selçukbiricik F, Kaşıkcıoğlu E, Sever MS: Is there a relation between duration of cyclosporine usage and right and left ventricular function in renal transplant patients?: Tissue Doppler echocardiography study. Transplantatıon Proceedıngs 36 (5): 1380- 1384, 2004.
  10. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, MacInness GT, Michell L, Plat F, Schork A, Smith B, Zanchetti A for the Value Trial Group (Koylan N in Steering Committeelist and Investigator list): Outcomes in hypertensive patients at high cardiovascular risk treated with regimes based on valsartan or amlodipine: The Value Randomized Trial. Lancet 363(9426): 2022-2031, 2004.
  11. Koylan N, Bilge, AK, Adalet K, Mercanoğlu F, Büyüköztürk K: Comparison of the effects of trimetazidine and diltiazem on exercise performance in patients with coronary heart disease. The Turkish Trimetazidine Study (TTS). Acta Cardiologica 59(6):644- 650, 2004.
  12. Pamukcu B, Oflaz H, Acar RD, Umman S, Koylan N, Umman B, Nisanci Y. The role of exercise on platelet aggregation in patients with stable coronary artery disease: exercise induces aspirin resistant platelet activation. J Thromb Thrombolysis. 2005 Aug;20(1):17-22.
  13. Koylan N, Acarturk E, Canberk A, Caglar N, Caglar S, Erdine S, Guneri S, Ilerigelen B, Kabakci G, Onder R, Sagkan O, Buyukozturk K. Effect of irbesartan monotherapy compared with ACE inhibitors and calcium-channel blockers on patient compliance in essential hypertension patients: A multicenter, open-labeled, three-armed study. Blood Press. 2005 Jul 1;14 Suppl 1:23-31.
  14. Oflaz H, Cuhadaroglu C, Pamukcu B, Meric M, Ece T, Kasikcioglu E, Koylan N. Endothelial Function in Patients with Obstructive Sleep Apnea Syndrome but without Hypertension. Respiration 2006, 73(6): 751- 756.
  15. Julius S, Weber MA, Kjeldsen SE, McInnes GT, Zanchetti A, Brunner HR, Laragh J, Schork MA, Hua TA, Amerena J, Balazovjech I, Cassel G, Herczeg B, Koylan N, Magometschnigg D, Majahalme S, Martinez F, Oigman W, Seabra Gomes R, Zhu JR. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. Hypertension. 2006 48(3):385-91.
  16. 16) Buyukozturk K, Ilerigelen B, Kabakci G, Koylan N, Kozan O. Intensive Cardiovascular Examination regarding Blood pressure levels: Evaluation of Risk Groups. ICEBERG study. BLOOD PRESSURE 2006, 15(5): 291- 301.
  17. Pamukcu B, Oflaz H, Onur M, Oncul A, Umman B, Koylan N, Bugra Z, Meric M, Nisanci Y. Aspirin-resistant platelet aggregation in a cohort of patients with coronary heart disease. BLOOD COAGULATION & FIBRINOLYSIS 2007, 18(5): 461-465.
  18. Deedwania P, Stone PH, Merz CNB, Cosin-Aguilar J, Koylan N, Luo D, Ouyang P, Piotrowicz R, Schenck-Gustafsson K, Sellier P, Stein JH, Thompson PL, Tzivoni D. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease – Results of the Study Assessing Goals in the Elderly (SAGE). CIRCULATION 2007, 115(6):700-707.
  19. Kabakçı G, Koylan N, İlerigelen B, Kozan Ö, Büyüköztürk K. The impact of dyslipidemia on cardiovascular risk stratification of hypertensive patients and association of lipid profile with other cardiovascular risk factors: Results from the ICEBERG study. Türk Kardiyol Dern Arş. (Arch Turk Soc Cardiol) 2007;35(8):458-466
  20. Kabakci G, Koylan N, Kozan O, Buyukozturk K, Ilerigelen B; ICEBERG Investigators. Evaluation of the metabolic syndrome in hypertensive patients: results from the ICEBERG Study. J Cardiometab Syndr. 2007 Summer;2(3):168-73.
  21. Kozan O, Buyukozturk K, Ilerigelen B, Kabakci G, Koylan N; ICEBERG Investigators. The impact of plasma high-sensitivity C-reactive protein levels on cardiovascular risk stratification of hypertensive patients: results of the ICEBERG study. J Clin Hypertens (Greenwich). 2007 Jul;9(7):500-5.
  22. Kabakci G, Koylan N, Ilerigelen B, Kozan O, Buyukozturk K. Impact of dyslipidemia on cardiovascular risk stratification of hypertensive patients and association of lipid profile with other cardiovascular risk factors: results from the ICEBERG study. Integr Blood Press Control. 2008;1:5-13. Epub 2008 Nov 2.
  23. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U; EUROASPIRE Study Group. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil. 2009 Apr;16(2):121-37.
  24. Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, Riegger GA, Malbecq W, Smith RD, Guptha S, Poole-Wilson PA; HEAAL Investigators. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet. 2009 Nov 28;374(9704):1840-8. Erratum in: Lancet. 2009 Dec 5;374(9705):1888.
  25. Tokgözoğlu L, Kaya EB, Erol C, Ergene O; EUROASPIRE III Turkey Study Group. EUROASPIRE III: a comparison between Turkey and Europe. Turk Kardiyol Dern Ars. 2010 Apr;38(3):164-72.
  26. Prugger C, Keil U, Wellmann J, de Bacquer D, de Backer G, Ambrosio GB, Reiner Z, Gaita D, Wood D, Kotseva K, Heidrich J; EUROASPIRE III Study Group. Blood pressure control and knowledge of target blood pressure in coronary patients across Europe: results from the EUROASPIRE III survey. J Hypertens. 2011 Aug;29(8):1641-8
  27. Kozan O, Ozcan EE, Sancaktar O, Kabakcı G; Turkish investigators of the i-SEARCH study. The prevalence of microalbuminuria and relevant cardiovascular risk factors in Turkish hypertensive patients. Turk Kardiyol Dern Ars. 2011 Dec;39(8):635-45
  28. Julius S, Palatini P, Kjeldsen SE, Zanchetti A, Weber MA, McInnes GT, Brunner HR, Mancia G, Schork MA, Hua TA, Holzhauer B, Zappe D, Majahalme S, Jamerson K, and Koylan N. Usefulness of Heart Rate to Predict Cardiac Events in Treated Patients with High Risk Systemic Hypertension. Am J Cardiol. 2012 Mar 1;109(5):685-92.
  29. Prugger C, Wellmann J, Heidrich J, De Bacquer D, Perier MC, Empana JP, Reiner Ž, Fras Z, Jennings C, Kotseva K, Wood D, Keil U; EUROASPIRE Study Group. Passive smoking and smoking cessation among patients with coronary heart disease across Europe: results from the EUROASPIRE III survey. Eur Heart J. 2014 Mar;35(9):590-8
  30. Gyberg V, De Bacquer D, Kotseva K, De Backer G, Schnell O, Sundvall J, Tuomilehto J, Wood D, Rydén L; EUROASPIRE IV Investigators. Screening for dysglycaemia in patients with coronary artery disease as reflected by fasting glucose, oral glucose tolerance test, and HbA1c: a report from EUROASPIRE IV–a survey from the European Society of Cardiology. Eur Heart J. 2015 May 14;36(19):1171-7.
  31. Seravalle G, Koylan N, Nalbantgil I, Caglar N, Quarti-Trevano F, Makel W, Grassi G, Fici F. HYT-hypertension in Turkey: a cross-sectional survey on blood pressure control with calcium channel blockers alone or combined with other antihypertensive drugs. High Blood Press Cardiovasc Prev. 2015 Jun;22(2):165-72
  32. Gyberg V, De Bacquer D, De Backer G, Jennings C, Kotseva K, Mellbin L, Schnell O, Tuomilehto J, Wood D, Rydén L, Amouyel P, Bruthans J, Conde AC, Cifkova R, Deckers JW, De Sutter J, Dilic M, Dolzhenko M, Erglis A, Fras Z, Gaita D, Gotcheva N, Goudevenos J, Heuschmann P, Laucevicius A, Lehto S, Lovic D, Miličić D, Moore D, Nicolaides E, Oganov R, Pająk A, Pogosova N, Reiner Z, Stagmo M, Störk S, Tokgözoğlu L, Vulic D; EUROASPIRE Investigators. Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology. Cardiovasc Diabetol. 2015 Oct 1;14:133
  33. Fici F, Seravalle G, Koylan N, Nalbantgil I, Cagla N, Korkut Y, Quarti-Trevano F, Makel W, Grassi G. Follow-up of Antihypertensive Therapy Improves Blood Pressure Control: Results of HYT (HYperTension survey) Follow-up. High Blood Press Cardiovasc Prev. 2017 Sep;24(3):289-296
  34. Koçyiğit D, Tokgözoğlu L, Kayıkçıoğlu M, Altay S, Aydoğdu S, Barçın C, Bostan C, Çakmak HA, Çatakoğlu AB, Emet S, Ergene O, Kalkan AK, Kaya B, Kaya C, Kaymaz C, Koylan N, Kültürsay H, Oğuz A, Özpelit E, Ünlü S. Is there a gender gap in secondary prevention of coronary artery disease in Turkey? Turk Kardiyol Dern Ars. 2018 Dec;46(8):683-691.
  35. Koylan N. Pitavastatin – tolerabilite ve yan etki profili. Turk Kardiyol Dern Ars. 2017 Apr;45(Suppl 3):16-23.
  36. Çetinkalp Ş, Koylan N, Özer N, Onat A, Özgen AG, Koldaş ZL, Sain Güven G, Özdoğan Ö, Karşıdağ K, Yiğit Z, Kayıkçıoğlu M, Tokgözoğlu L, Can LH, Tartan Z, Kültürsay H, Karpuz B, Kırılmaz B, Ersanlı M, Ural D, Erbakan AN, Oğuz A, Kayıkçıoğlu ÖR, Temizhan A, Sansoy V, Ceyhan C, Öngen Z, Bayram F, Örem C, Sönmez A, Beyaz Ş, Ükinç K, Şarer Yürekli B, Çoker M, Canda E, Yıldırım Şimşir I. 33 soruda trigliseritler ve kardiyovasküler etkileri. Turk Kardiyol Dern Ars. 2017 Mar;45(Suppl 1):1-63.
  37. Tokgözoğlu L, Kayıkçıoğlu M, Altay S, Aydoğdu S, Barçın C, Bostan C, Çakmak HA, Çatakoğlu AB, Emet S, Ergene O, Kalkan AK, Kaya B, Tulunay Kaya C, Kaymaz C, Koylan N, Kültürsay H, Oğuz A, Özpelit E, Ünlü S. EUROASPIRE-IV: Avrupa Kardiyoloji Derneğinin koroner arter hastalarında yaşam tarzı, risk faktörleri ve tedavi yaklaşımı üzerine çalışması: Türkiye verileri. Turk Kardiyol Dern Ars. 2017 Mar;45(2):134-14411.

TEXTBOOK CHAPTERS, INVITED ARTICLES AND REVIEWS

  1. Büyüköztürk K, Koylan N, Meriç M, Korkut F, Özsaruhan Ö, Nişancı Y, Güven Ö, Deligönül U, Erzengin F, Özkan E: The effect of oral verapamil in the treatment of essential hypertension. In: “Hypertension- The next decade: Verapamil in Focus”, Eds.: A. Fleckenstein and JH Laragh, Churchill- Livingstone, p: 199- 204, 1987.
  2. Buğra Z, Meriç M, Koylan N, Adalet K, Nişancı Y, Büyüköztürk K, Ertem G: Long- term effects of coronary angioplasty on signal averaged electrocardiogram. In: “Volumetto Estratto da ICPEP 93”, Editor: A. Oto, Monduzzi Editore S.p.A, Bologna, Italy, p. 15- 18, 1993.
  3. Meriç M, Koylan N, Büyüköztürk K: Balloon Mitral Valvuloplasty. In: “Textbook of Angiology”, Ed. Chang JB, Springer- Verlag, New York, Berlin, Heidelberg, 2000. pp: 370- 380.
  4. Özben B, Bilge, AK, Koylan N: Cardiovascular aging and cardiovascular diseases in the elderly. In “Frontiers in Neurodegenerative Disorders and Aging: Fundamental aspects, Clinical Perspectives and New Insights”. Eds. T. Özben and M Chevion. IOS Press, 2004, pp: 128- 149.

Sosyal Medya Bağlantılarımız
Başa dön